Jaradat Nour Jamal, Hatmal Mamon, Alqudah Dana, Taha Mutasem Omar
Department of Medical Laboratory Sciences, Faculty of Applied Health Sciences, The Hashemite University, P.O. Box 330127, Zarqa, 13133, Jordan.
Cell Therapy Center, the University of Jordan, Amman, 11942, Jordan.
J Comput Aided Mol Des. 2023 Dec;37(12):659-678. doi: 10.1007/s10822-023-00528-y. Epub 2023 Aug 19.
STAT3 belongs to a family of seven transcription factors. It plays an important role in activating the transcription of various genes involved in a variety of cellular processes. High levels of STAT3 are detected in several types of cancer. Hence, STAT3 inhibition is considered a promising therapeutic anti-cancer strategy. However, since STAT3 inhibitors bind to the shallow SH2 domain of the protein, it is expected that hydration water molecules play significant role in ligand-binding complicating the discovery of potent binders. To remedy this issue, we herein propose to extract pharmacophores from molecular dynamics (MD) frames of a potent co-crystallized ligand complexed within STAT3 SH2 domain. Subsequently, we employ genetic function algorithm coupled with machine learning (GFA-ML) to explore the optimal combination of MD-derived pharmacophores that can account for the variations in bioactivity among a list of inhibitors. To enhance the dataset, the training and testing lists were augmented nearly a 100-fold by considering multiple conformers of the ligands. A single significant pharmacophore emerged after 188 ns of MD simulation to represent STAT3-ligand binding. Screening the National Cancer Institute (NCI) database with this model identified one low micromolar inhibitor most likely binds to the SH2 domain of STAT3 and inhibits this pathway.
信号转导和转录激活因子3(STAT3)属于由七个转录因子组成的家族。它在激活参与多种细胞过程的各种基因的转录中起重要作用。在几种类型的癌症中检测到高水平的STAT3。因此,抑制STAT3被认为是一种有前景的抗癌治疗策略。然而,由于STAT3抑制剂与该蛋白的浅SH2结构域结合,预计水合水分子在配体结合中起重要作用,这使得发现强效结合剂变得复杂。为了解决这个问题,我们在此提议从与STAT3 SH2结构域复合的强效共结晶配体的分子动力学(MD)框架中提取药效团。随后,我们采用遗传函数算法与机器学习(GFA-ML)相结合的方法,探索MD衍生药效团的最佳组合,以解释一系列抑制剂之间生物活性的差异。为了增加数据集,通过考虑配体的多个构象,训练和测试列表增加了近100倍。经过188纳秒的MD模拟后,出现了一个单一的重要药效团来代表STAT3-配体结合。用该模型筛选美国国立癌症研究所(NCI)数据库,确定了一种低微摩尔浓度的抑制剂,它最有可能与STAT3的SH2结构域结合并抑制该途径。